Lilly’s Alzheimer’s EXPEDITION3 Proves Positive For Biogen’s Anti-Amyloid At CTAD

Lilly’s Phase III EXPEDITION3 results for solanezumab at CTAD contribute data to the Alzheimer’s field about the role of amyloid in disease progression, including the effect that other amyloid-targeting antibodies may have in ongoing clinical trials, such as Biogen’s Phase III candidate aducanumab.